Suven Life Sciences is currently trading at Rs. 190.30, up by 9.05 points or 4.99% from its previous closing of Rs. 181.25 on the BSE.
The scrip opened at Rs. 183.10 and has touched a high and low of Rs. 192.00 and Rs. 183.10 respectively. So far 153067 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 250.80 on 29-Jan-2018 and a 52 week low of Rs. 155.00 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 192.00 and Rs. 179.00 respectively. The current market cap of the company is Rs. 2418.37 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.35% and 32.65% respectively.
Suven Life Science has undergone US Food and Drug Administration (USFDA) renewal inspection at their facility in Pashamylaram near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP during February 5 - 15, 2018.
Based on this USFDA inspection and the review thereafter, the facility is considered to be in an acceptable state of compliance with regards to Current Good Manufacturing Processes (CGMP) and the agency has determined that the inspection classification of this facility is No Action Indicated (NAI).
Also, USFDA has concluded that the inspection is closed and the agency has issued an Establishment Inspection Report (EIR) for its facility at Pashamylaram. So far, the company has filed 19 DMF’s and 5 ANDA’s from this facility which is USFDA complaint under cGMP and continued after renewal inspection.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: